Attendance at Endless Frontier Labs 2026

AI SummaryClose X

Coiled Therapeutics plc announced its participation in the Endless Frontier Labs (EFL) Frontiers 2026 event, showcasing its lead asset AO-252, a TACC3 inhibitor. The company was selected for the competitive nine-month EFL program, which has a 5% graduation rate and aims to accelerate the commercialization of science and deep-tech companies. Recent clinical trial data for AO-252 demonstrated an 80% Clinical Benefit Rate in a twice-daily cohort, indicating significant efficacy in heavily pre-treated patients. This participation offers valuable mentorship, investor access, and business development support, underscoring the potential impact of Coiled Therapeutics' technology in oncology.

Disclaimer*

UK 100

Latest directors dealings